AI Article Synopsis
- Registries provide valuable real-world data that complements findings from randomized controlled trials, especially for rare diseases like Waldenström macroglobulinaemia (WM).
- The paper by Uppal and colleagues discusses the Rory Morrison Registry, which is the UK registry dedicated to WM and IgM-related disorders.
- They emphasize the significant advancements in treatment options for WM, including first-line and relapse therapies, observed in recent years.
Article Abstract
Registries constitute an interesting source of real-world data and bring complementary information to randomised controlled trials. They are of particular importance in rare diseases such as Waldenström macroglobulinaemia (WM), which can present with various clinical and biological features. In their paper Uppal and colleagues describe the development of the Rory Morrison Registry, the UK registry for WM and IgM-related disorders and highlight the profound changes in therapies both at first-line and relapsed settings in the recent years. Commentary on: Uppal E. et al. The WMUK Rory Morrison Registry for Waldenström Macroglobulinaemia: the growth of a national registry for a rare disorder. Br J Haematol. 2023;201:905-912.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.18695 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!